+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections

European Commission

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to most of the following expected outcomes:

Researchers and developers make the best use of the state-of-the-art knowledge and resources for an effective development of new treatment options for patients suffering from difficult-to-treat infections.
Healthcare professionals and people living with difficult-to-treat infections are ultimately provided with the availability of clinically useful phage therapies.
Regulators are provided with quantifiable, verifiable and replicable data on safety and efficacy of phage therapy for human use and move faster towards market approval of novel phage-based therapies against antimicrobial resistant infections.
Citizens are engaged and informed on innovative phage-based treatments as alternative therapeutic options complementary to antibiotics.

Scope:

Antimicrobial resistance (AMR) has been identified by the United Nations (UN) General Assembly as a health Emergency in 2016. AMR is contributing to morbidity and mortality increasing the burden for society and healthcare costs. This is due to a worrying increase on the number of bacteria resistant to antibiotic treatment, causing chronic and often life-threatening infections such as wound and urinary tract infections. The World Health Organization (WHO) lists AMR among the top 10 threats for global health[1] and recognises that a lack of innovation is set to undermine antibiotic performance and health gains, with a major gap in the discovery of innovative antibacterial treatments[2].

Hence, there is an urgent need for the development of therapies to treat infections.

Bacteriophages (phages) represent a promising alternative or complement to antibiotics for the treatment of infections that do not respond to conventional treatment options. With the increase of AMR bacteria, both healthcare practitioners and innovators are expressing an increasing interest in the use of phages for the treatment of infections. As a result, the clinical use of phage therapy is expanding in the EU and beyond under different regulatory pathways, approaches and different conditions (e.g. magistral personalised phage preparations and fixed phage cocktails applied via compassionate use, named-patients based or expanded access programmes) despite a lack of large data on the efficacy of phage therapy for human use. So far, a few modest-sized randomised-controlled trials have been conducted providing indications for the safety and efficacy of the phage products, in agreement with preclinical animal studies. However, they could not always prove the efficacy of phage preparations.

Therefore, proposals should aim to develop phage-based therapies to treat bacterial infections that do not respond to conventional treatment options. For this, applicants should carry out multicenter, multinational randomised controlled clinical trial (RCT) to generate scientific evidence demonstrating safety and efficacy of phage-based therapy as stand-alone or in combination with standard-of-care (such as antibiotic or other innovative non-antibiotic-based treatment) for the treatment of difficult-to-treat bacterial infections.

Both approaches for phage therapy, personalised phage preparations or ready-to-use phage cocktails, are in scope with the call. Innovative study design, aiming at better capturing and evaluating the full potential of the benefit of personalised phage therapy, e.g. using regularly updated phage preparations, is welcome.

The topic is open to any pathogen causing difficult to treat infections mainly due to AMR or to biofilms, for any clinical indication and applying phage treatment in any route of administration. Applicants are encouraged to address pathogens listed in the WHO Bacterial Priority Pathogens List[3].

Lessons learned from previous clinical trials that failed[4] (e.g. PhagoBurn) should be considered for optimal study design, e.g. inclusions and logistics criteria, to favour success and conclusive results. The proposed trial should be designed with proper patient selection, diagnostic protocols (e.g. phagogram), production protocols (purification, stability, host selection, etc.) and treatment protocols (including dosage, repetition, duration, route of administration).

All available information about the characteristics of the phages to be used in the clinical trial should be provided (e.g. sequence, stability, targeted bacteria, registration in a phage bank or phage registry, etc.). Moreover, any additional indication of the use of phages for other applications than human use in the clinical trial (e.g. veterinary use, surface cleaning, food preservation) should be detailed in the proposal if available.

The use of computational modelling and/or artificial intelligence (AI) tools is encouraged to speed/optimise trial design, implementation and/or the analysis of large data. In the same way, the use of innovative in silico, in vitro or in vivo models to facilitate pre-clinical selection of phages to use in the clinical trial is welcome.

In their proposal applicants should describe how they take into account scientific advice or protocol assistance from the European Medicines Agency (EMA)[5]. In addition, applicants should provide a sound timeline on the trial protocol in their proposal. Furthermore, in their proposal applicants should also provide a delivery date for approval of the RCT protocol from the regulatory body(ies), which should be within 12 months from the start of the project.

Applicants should propose a clear exploitation pathway through the different necessary steps (research, manufacturing, regulatory approvals and licensing, Intellectual Property management, etc.) in order to accelerate marketing authorisation and uptake by the health systems.

The participation of start-ups, micro, small and medium-sized enterprises (SMEs)[6] is encouraged with the aim of strengthening their scientific and technological foundations, enhancing their innovation potential, and exploring possibilities for commercial exploitation.

Proposals should adhere to the FAIR[7] data principles, adopt wherever relevant, data standards and data sharing/access good practices, and apply good practices for GDPR[8] compliant personal data protection.

Sex and gender-related differences should be addressed, where relevant. To ensure that the needs of patients living with chronic infections are adequately addressed and that there is public acceptability and confidence on innovative phage-based therapies, the involvement of patient and/or civil society representatives in all phases of the research and development process is strongly encouraged. For this, the topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.

Applicants should provide details of their clinical studies[9] in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged.

AI Based Application Success Predictor

🧪 1. Scientific Excellence Is Paramount

For ERC grants, excellence is the sole selection criterion—evaluations focus exclusively on the quality of the research and track record .

Peer-reviewers adhere strictly to predefined criteria (e.g., Horizon ITN evaluations), and weaknesses—rather than strengths—often decide the outcome .

🌍 2. Strategic Alignment with EU Priorities

Horizon Europe emphasizes Green & Digital Transitions and resilience, with specific budget steering across biodiversity, climate, digital, and societal missions .

Proposals that clearly align with these strategic orientations and EU missions are significantly more competitive.

🤝 3. Strong, Diverse European Consortia

Horizon projects demand well-balanced consortia across Europe—geographically and disciplinarily diverse, including academia, industry, SMEs, NGOs .

Effective leadership, communication, trust, and active collaboration are key success factors.

🧴 4. Proven Research Infrastructure & Track Record

A strong publication record—especially in high-impact venues—and prior grant awards bolster chances .

ERC starting, consolidator, or advanced grants require exceptional citation records, strong proposals, and investigator track records .

📈 5. Robust Project Management

For large collaborative grants, project coordination, administration, and communication are just as crucial as scientific content .

Demonstrating realistic budget planning (100% direct costs + 25% indirect costs), administrative frameworks, and governance structures strengthens proposals .

💼 6. Fostering Mobility & Career Growth

Marie Skłodowska-Curie fellowships emphasize researcher mobility, interdisciplinary training, and developing future talent .

🧷 7. Geographical & Gender Equity

Northern and certain Eastern European institutions currently have higher success rates (≈22% vs below 18% in Southern Europe) .

ERC gender data: male and female applicants have similar success rates, though male applicants apply more frequently .

📌 Key Takeaways

Factor	Why It Matters
Excellence-first	Superior science and investigator record are non-negotiable.
Strategic fit	Alignment with EU green, digital, and mission goals is essential.
Consortium quality	Geographic, sectoral, and expertise balance enhances impact.
Management capacity	Good PM builds confidence in successful delivery.
Experience track record	Publications, previous funding, and citations build credibility.
Mobility & careers	MSCA focuses on researcher development and interdisciplinary collaboration.

🧭 Applicant Tips

Master criteria & avoid weaknesses: Make sure your proposal addresses common reviewer pitfalls—methodology, innovation, budget clarity.

Map to EU priorities: Explicitly connect your objectives to Horizon Europe’s strategic plan (2025–2027).

Build strong consortia early: Prioritize complementary expertise, geography, gender balance, and partner roles.

Show robust project management: Include a Work Package structure, governance plans, and clear communication strategies.

Leverage your track record: Highlight high-impact papers, leadership in projects, and previous awards.

Consider MSCA opportunities: Use them for mobility grants or integrating training into your project.

✅ In Summary

To maximize success with European Commission grants—especially ERC or Horizon Europe—focus relentlessly on scientific excellence, strategic EU alignment, consortium strength, and solid project planning. Combine these with a strong publication record and researcher development elements, and aim to close off any potential reviewer concerns.

Eligibility Requirements

General conditions

1. Admissibility Conditions, Proposal page limit and layout

Admissibility Conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.

Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.

2. Eligible Countries

Eligible Countries are described in Annex B of the Work Programme General Annexes.

A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.

3. Other Eligible Conditions

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.

If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).

The following exceptions apply: subject to restrictions for the protection of European communication networks.

Other Eligible Conditions are described in Annex B of the Work Programme General Annexes.

4. Financial and operational capacity and exclusion

Financial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.

5a. Evaluation and award: Award criteria, scoring and thresholds

Evaluation and award: Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.

5b. Evaluation and award: Submission and evaluation processes

The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.

Evaluation and award: Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.

5c. Evaluation and award: Indicative timeline for evaluation and grant agreement

Evaluation and award: Indicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.

6. Legal and financial set-up of the grants

Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [[This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf]].

Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.

Specific conditions

Specific conditions are described in the specific topic of the Work Programme.

Sponsor Details

Sponsor Institute/Organizations: European Commission

Sponsor Type: Corporate/Non-Profit

Address: Rue de la Loi 200, 1049 Brussels, Belgium

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity